课题基金 / 基金详情

HUMAN GROWTH HORMONE RELEASING FACTOR IN LONG TERM TREATMENT OF CHILD

HUMAN GROWTH HORMONE RELEASING FACTOR IN LONG TERM TREATMENT OF CHILD
儿童长期治疗中的人类生长激素释放因子
批准号：
6308580
负责人：
STEPHEN M ROSENTHAL
金额：
$1.75万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
依托单位国家：
美国
项目类别：
财政年份：
1999
资助国家：
美国
项目状态：
已结题
起止时间：
1999-12-01 至 2000-11-30
来源：
https://reporter.nih.gov/project-details/6308580
关键词：
child (0-11) child physical development clinical research endocrine disorder growth hormone releasing hormone hormone therapy human subject human therapy evaluation postnatal growth disorder somatotropin

项目摘要

项目成果

STEPHEN M ROSENTHAL的其他基金

相关文献

中文摘要
翻译
本研究的主要目的是评估在12-24个月期间每天皮下注射一次GRF 1-44在刺激下丘脑源性生长激素分泌缺陷儿童生长速度方面的耐受性和有效性。这项研究由ICN制药公司赞助，是一项第三阶段、每日单一给药、非随机、开放的门诊研究，每个患者作为他/她自己的对照。6个月后将根据生长速度进行疗效评估。
英文摘要
The primary objective of this study is to evaluate the tolerability and efficacy of the once-a-day subcutaneous administration of GRF 1-44 during 12-24 months in stimulating growth velocity in children with documented growth hormone secretion deficiency of hypothalamic origin. This study, sponsored by ICN Pharmaceuticals, Inc, is a Phase III, single daily administration, non-randomized, open, outpatient study, with each patient serving as his/her own control. Efficacy will be assessed after 6 months based on growth rate.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
IGFS AND SKELETAL MUSCLE CELL DIFFERENTIATION
IGFS AND SKELETAL MUSCLE CELL DIFFERENTIATION
IGFS AND SKELETAL MUSCLE CELL DIFFERENTIATION
IGFS AND SKELETAL MUSCLE CELL DIFFERENTIATION